Global Pleural Catheters Market - 2023-2030

Global Pleural Catheters Market - 2023-2030

Market Overview

The global pleural catheters market size was valued US$ YY million in 2022 and is estimated to reach US$ YY million by 2030, growing at a CAGR of 6.2% during the forecast period (2023-2030).

The pleural catheter is a flexible tube inserted through an incision (cut) in the chest and placed in the pleural cavity. The catheter sits in the pleural cavity and has many holes to collect the extra fluid. Pleural catheters are used as a first-line therapy to improve patient quality of life, patient safety, and clinician efficiency—freedom from hospitalization and effective symptomatic relief with minimal interventions.

Market Dynamics

Pleural catheters are becoming more popular worldwide as a treatment option for malignant pleural effusions when pleurodesis has failed or is contraindicated. Pleural catheters are used as first-line therapy to improve patient quality of life, safety, and clinician efficiency. Some critical factors driving the growth of the pleural catheter market include eliminating hospital admissions and providing effective symptomatic relief with minimal interventions.

The increasing prevalence of the cardiovascular disease worldwide is expected to drive market growth.

According to the Centers for Disease Control and Prevention, 2020, heart disease killed 382,776 men (1 in 4 male deaths) and 314,186 women (1 in 5 female deaths). CVDs are a group of heart and blood vessel disorders, including coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. More than four of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70.

The most common cause of the pleural effusion is congestive heart failure (CHF). When increased hydrostatic pressure in the pleural microcirculation exceeds the capacity of lymphatic vessels to reabsorb the excess fluid, fluid accumulates in the pleural space. Although pleural effusion occurs in approximately 70% of CHF patients, treatment of the underlying disease usually results in fluid reabsorption. In symptomatic patients, therapeutic thoracentesis is frequently considered while waiting for a pharmacological treatment effect. Patients may experience recurrent symptomatic pleural effusions despite optimal medical management. Therefore, indwelling pleural catheters are effective and well tolerated in congestive heart failure, have a low complication rate, and may be considered a reasonable treatment option, particularly for nontransplant candidates. Thus, from the above factors, the market is expected to drive in the forecast period..

Complications Associated with pleural catheters are expected to hamper the market growth.

Pleural catheters are commonly used in patients suffering from recurrent heart-related chronic diseases. Although they are simple to insert without sedation, many complications are associated with their use. Catheter-related pleural infections are the most common in patients. Other risks associated with using pleural catheters in patients include catheter tract metastases, severe chest pain, tube dislocation, etc. Such complications related to the long-term presence of pleural catheters in the body can cause problems for patients, hampering market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has created new challenges for pleural disease management. Routine medical practice and service provision for pleural diseases have been severely disrupted as resources and personnel have been redirected to manage acutely ill COVID-19 patients. This has also resulted in significant disruptions in the delivery of pleural and lung cancer services, with guidelines being updated regularly to reflect the ever-changing landscape of this pandemic. For instance, the British Thoracic Society (BTS) COVID-19 recommendations advocate for the continuation of diagnostic pathways for suspected cancer to reduce hospital visits and admissions while ensuring patient and staff safety. Moreover, patients with symptomatic malignant pleural effusions are advised to undergo either large-volume therapeutic aspirations or first-line indwelling pleural catheters (IPC), avoiding the need for hospitalization for chest drain and talc pleurodesis. Family members should be trained to drain IPCs whenever possible, reducing the risks posed by multiple district nurse visits. Depending on local expertise, patients with cancer who are candidates for anti-cancer therapy should have a day-case medical thoracoscopy with/without an IPC or image-guided pleural biopsies. Thus, from the above factors, the market got affected and is expected to improve in the forecast period.

Segment Analysis

Malignant Pleural Effusions segment is expected to hold the largest market share in pleural catheters

The malignant pleural effusions segment accounted for the largest market share in 2021. Many diseases can cause pleural effusion. It has been observed in infections, other diseases, and cancers. In general, fluid accumulates in the pleural space when there is an excess of fluid, a decrease in fluid absorption, or both. If the effusion is caused by cancer cells in the fluid, it is referred to as a ""malignant pleural effusion"" or MPE. When cells from lung cancer or another type of cancer spread to the pleural space, an MPE forms. These cancer cells increase pleural fluid production while decreasing fluid absorption.

Furthermore, people with lung cancer, breast cancer, and lymphoma (lymphatic tissue cancer) are more likely to get an MPE. Another common cause of MPE is mesothelioma (a rare cancer of the pleura). MPE can also be caused by cancer that has spread from the stomach, kidney, ovaries, or colon. Therefore, the increasing prevalence of cancer worldwide is expected to drive market growth in the forecast period. For instance, according to GLOBOCAN 2020, the number of new cancer cases diagnosed in 2020 is estimated to be 19.3 million, with nearly 10.0 million deaths due to cancer. GLOBOCAN predicts that cancer cases will reach 28.4 million by 2040. Female breast cancer has surpassed lung cancer as the most common cancer in the world (11.7%), followed by lung (11.4%), colorectal (10.0%), prostate (7.3%), and stomach (5.6%).

Additionally, in terms of cancer-related mortality, lung cancer is the leading cause, accounting for 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%). Men are more likely to develop lung, prostate, and colorectal cancers, whereas women are more likely to develop breast, colorectal, and lung cancers. The top ten cancers account for more than 60% of cancer incidence and 70% of cancer mortality. As a result, the demand for indwelling pleural catheters (IPC) has increased because this device is a small catheter placed under your skin and into the pleural fluid, allowing for repeated drainage at home (without any more needle sticks) to relieve symptoms. These catheters are placed as an outpatient procedure under local anesthesia. The catheter is safe and simple to use and may eventually allow the lung to expand fully up to the chest wall. After the fluid buildup subsides, many patients can have the catheter removed after 2-3 months. Thus, from the above factors, the market segment accounted for the largest market share in the forecast period.

Geographical Analysis

North America region holds the largest market share in the global pleural catheters market

North America region accounted for the largest market share in 2021. The increasing prevalence of pleural diseases, rising cases of cardiovascular disease, cancer and infectious disease, increasing number of thoracic surgeries, increasing demand for minimally invasive processes and favorable reimbursement policies are the factors to drive the market in the forecast period. For instance, according to the National Center For Biotechnology Information Report 2022, pleural effusion is the most common pleural disease, affecting 1.5 million patients in the United States annually. Pleural effusions can be caused by a variety of conditions, including lung diseases such as pneumonia and asbestos exposure, systemic diseases such as lupus and rheumatoid arthritis, or the pleural manifestation of diseases that affect other organs such as congestive heart failure, pancreatitis, or conditions local to the pleura such as pleural infections and mesothelioma. Therefore, it has increased the demand for pleural catheters. Thus, from the above factors, the North American region accounted for the largest market share in the forecast period.

Competitive Landscape

Major key players in the pleural catheters market are Medtronic, Teleflex Incorporated, Ply Gem Holdings Inc, Smiths Group plc, Medela AG, ATMOS MedizinTechnik GmbH & Co. KG, ARGON MEDICAL, BD, MAQUET Holding B.V. & Co. KG, LivaNova PLC and Cook Medical.

Teleflex Incorporated:

Overview:

Teleflex Incorporated is an American provider of specialty medical devices for various critical care and surgical procedures. The firm reports seven segments: vascular access, interventional, surgical, anesthesia, interventional urology, original-equipment manufacturing, and all others. Teleflex is the home of Arrow, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck – trusted brands united by a common sense of purpose. The company's geographic exposure is predominantly in the United States, accounting for 60% of revenue, with overseas markets accounting for the remaining 40%.

Product Portfolio

Arrow-Clarke Thoracentesis Device: The Arrow-Clarke Thoracentesis Device permits the removal of fluids from the pleural space and provides access to infuse chemotherapeutic or sclerosing agents.

The global pleural catheters market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.